[Improved survival in patients with prostate cancer]

Strahlenther Onkol. 2016 Nov;192(11):825-826. doi: 10.1007/s00066-016-1045-1.
[Article in German]
No abstract available

MeSH terms

  • Adult
  • Aged
  • Androgen Antagonists / administration & dosage*
  • Chemoradiotherapy / mortality*
  • Chemoradiotherapy / statistics & numerical data*
  • Disease-Free Survival
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Prostatic Neoplasms / mortality*
  • Prostatic Neoplasms / therapy*
  • Retrospective Studies
  • Risk Factors
  • Survival Rate
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Androgen Antagonists